Eterna Therapeutics (ERNA) Total Debt to Capital

Eterna Therapeutics - graphic logo of issuer ERNA

Eterna Therapeutics (ERNA) specializes in developing mRNA drugs with a complex biomaterial delivery system, while the asset's market value dynamics show that the current figure is 0.11. The financial model relies on the development of cell-based blood therapies funded by insurance organizations. However, strict FDA oversight of genetic editing and a liquidity shortage in the biotech industry are slowing the expansion of the partner network and the growth of the customer base.

Eterna Therapeutics, Inc. (ERNA): Debt to Equity Ratio from 04/28/2023 to 10/31/2026

Metric breakdowns and analytics for Eterna Therapeutics Inc. (ERNA)

- share price and consensus valuation forecast:
Stock Price Eterna Therapeutics, Inc.|ERNA - Consensus Target
- market capitalization details:
Market Capitalization Eterna Therapeutics|ERNA - Enterprise Value
- book capitalization indicators:
Net Assets per Single Share Eterna Therapeutics|ERNA - Accounting Capitalization|Market Capitalization to Book Value Ratio eternatx.com|ERNA - Cumulative Company Assets
- debt and liquidity details:
Total Debt to Capital Eterna Therapeutics|ERNA - Long-Term Liabilities to Capital|Short-Term Debt to Equity Eterna Therapeutics, Inc.|ERNA - Aggregate Debt Obligations|Debt to Book Value Eterna Therapeutics|ERNA - Company Long-Term Loans and Borrowings|Company Short-Term Debts Eterna Therapeutics|Quick Liquidity eternatx.com
- net income and valuation ratios data:
ERNA - Company Net Income
Fundamental company valuation:Eterna Therapeutics
Finished products of Eterna Therapeutics, Inc.

Diversifying the production sites of Eterna Therapeutics (ERNA) to ensure the continuity of cellular component supplies requires significant capital expenditures. By analyzing the total debt-to-equity ratio, an investor assesses the balance between debt financing and equity: a decrease in this ratio confirms the financial stability of assets, yet it may limit the overall return on investment due to the abandonment of financial leverage.

Competitor analysis for Eterna Therapeutics

TGTX (TG Therapeutics) - Total Debt to Capital|Total Debt to Equity Ratio Arcellx Inc (ACLX)|Total Debt to Capital IRON|Total Debt to Capital Syndax Corp (SNDX)|Debt to Equity Kura Oncology, Inc. KURA|ADCT: Debt to Equity Ratio|Foghorn - Total Debt to Capital|Vor Biopharma, Inc. (VOR) - Total Debt to Equity Ratio|NKTX: Total Debt to Capital|Debt to Capital Coeptis Therapeutics, Inc. (COEP)|Debt to Equity Actinium Pharmaceuticals|ESLA: All Debt to Shareholders' Equity Ratio|Total Debt to Equity Ratio CASI (CASI Pharmaceuticals)|MRKR (markertherapeutics.com) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital INAB (IN8bio, Inc)|GT Biopharma Corporation - Debt to Equity|APTO - Debt to Equity|BPTH: Debt to Equity|MEI Pharma (MEIP) - Debt to Equity|Debt to Capital Vincerx Pharma (VINC)